There are many phases in a woman's life, menarche, menstruations, pregnancy, postpartum and menopause. Each phase comes with its own challenges, and changes the way of looking at life. However, narrowing to one, today we are focusing on weight gain after menopause. Gaining weight is a common concern for many women are approaching menopause. This period brings hormonal changes, shifts in activity levels and effects of aging. All of these contribute to weight gain. However, not everyone experiences weight gain during menopause, and individual experiences may vary greatly.

Menopause and Its Life Phases

Before diving into the specifics of weight gain, it’s helpful to understand the terminology associated with menopause:

• Premenopause refers to the period between puberty and the commencement of perimenopause.
• Perimenopause is the transitory period before menopause, characterized by fluctuating reproductive hormones.
• Menopause is defined as the absence of menstrual cycles for 12 consecutive months.
• Postmenopause is the period following menopause; typically used interchangeably with "menopause."

Hormonal Changes and Weight Gain

Hormones influence weight fluctuations after menopause, specifically how fat is distributed and how the body controls hunger.

Fat Content and Distribution

The hormonal fluctuations of perimenopause and menopause influence where fat is stored in the body:

Perimenopause: During this phase, estrogen levels fluctuate while progesterone levels decline steadily. In early perimenopause, higher estrogen levels can promote fat storage in the hips and thighs as subcutaneous fat, which generally carries fewer health risks.

Menopause: As estrogen levels drop significantly, fat storage shifts to the abdominal area as visceral fat.

This type of fat surrounds internal organs and is associated with health risks like:

• Insulin resistance
• Type 2 diabetes
• Heart disease
• Other metabolic issues

Appetite Regulation

Lower estrogen levels during perimenopause can have an impact on appetite management. A 2019 analysis found that decreased estrogen may diminish satiety signals, making you feel less full after meals. This might lead to increased calorie consumption and weight gain.

The Effect of Age on Weight

Weight gain during menopause is attributed to more than just hormonal changes. Several elements come into play throughout the aging process:

Increased fat content and decreased muscle mass: These changes affect the body's resting energy expenditure (REE), which means fewer calories are expended when at rest.

Lower activity levels: Fatigue, sleep difficulties, and menopause-related symptoms can all lead to a decrease in physical activity, further reducing REE and increasing weight.

Managing Weight Gain During Menopause

If you are concerned about weight gain during menopause, a variety of strategies can help you manage it effectively. It is usually recommended that you speak with a healthcare practitioner before developing a specific approach.

Dietary modifications

Focus on a well-balanced diet that includes less carbohydrates, more fiber, and less added sugar and salt.

Include nutrient-dense meals to boost overall health.

Physical exercise

Regular exercise helps to maintain muscle mass and reduce body fat. Strength training, aerobic, and flexibility exercises are quite beneficial.

If you have osteoporosis, see your doctor about safe activity options.

Rest and Stress Management

Prioritize sleep and relaxation to combat fatigue and stress, both of which can contribute to weight gain.

Mindfulness practices or yoga may help reduce stress levels.

Originally developed to treat type 2 diabetes and obesity, GLP-1 receptor agonists have shown benefits beyond blood sugar control and weight loss, including for cardiovascular and kidney health.

Some women, particularly those with polyendocrine metabolic ovarian syndrome (PMOS), formerly known

as PCOS, have reported conceiving after taking these medications.

Although GLP-1 drugs can support weight loss and improve metabolic health, evidence that they directly improve fertility remains limited.

Woman Says GLP-1 Drug Helped Her Conceive

For 30-year-old Ashlee Amborn, pregnancy was challenging. According to ABC News, she had PMOS, one functioning fallopian tube and half a uterus, which complicated her chances of conceiving naturally.

After years of fertility treatments, she conceived her first two children. Four months after her second child's birth, she became pregnant again.

Amborn said a GLP-1 drug prescribed to manage her PMOS symptoms, including inflammation and hormonal imbalances, helped her conceive. She became pregnant after taking the medication for a month.

"It was kind of these mixed emotions of, 'Holy cow, I'm pregnant,'" Amborn said. "I did this on my own without fertility treatment. All it took was a GLP-1."

Also read: Sorority Rush Sees Ozempic Trend: What Young Women Should Know Before Using GLP-1 Drugs

What Does Research Say?

A recent review published in the Journal of the Brazilian Reproduction Association (JBRA) Assisted Reproduction suggests a possible association between GLP-1 use and improved fertility outcomes in women with obesity and PMOS, particularly those also taking metformin, a medication used to manage blood sugar.

Weight loss and improved insulin sensitivity may support ovulation and reduce ovarian dysfunction. However, more research is needed to establish whether these medications improve pregnancy or live-birth rates.

Can GLP-1 Drugs Affect Ovulation?

Dr. Jacinta Anyaoku, a physician at Maven Clinic specializing in obesity and women's health in midlife, told ABC News that research has not established a direct link between GLP-1 use and ovulation rates, although she has observed potential benefits among her patients.

"When you lose weight, your inflammation goes down," Anyaoku said. "It actually can help with improving your rate of ovulation. Your egg quality could potentially improve if you have reduced inflammation, and so these are all potential effects that come with GLP-1 use."

Sharrón L. Manuel, a board-certified OB/GYN and reproductive endocrinology specialist at HRC Fertility, attributes the reported "Ozempic Baby Boom" largely to weight loss and improved metabolic health, which may help restore ovulation.

Excess body weight can disrupt the hypothalamic-pituitary-ovarian (HPO) axis, contribute to insulin resistance and affect egg and uterine lining quality.

Manuel also points to preliminary research suggesting GLP-1 drugs may influence reproductive function through hormonal regulation, reduced inflammation and improved insulin sensitivity. However, preclinical findings involving ovarian function and endometrial receptivity require further investigation in humans.

Read More: GLP-1 Drugs Ozempic, Zepbound Use Rises 24-Fold Among American Women After Childbirth

Can GLP-1 Drugs Be Used During Pregnancy?

GLP-1 drugs should not be used during pregnancy. Women planning to conceive should consult their healthcare professional about stopping treatment. For semaglutide, prescribing guidance recommends discontinuation at least two months before a planned pregnancy.

Women should also seek medical advice about using these medications while breastfeeding.

The American College of Obstetricians and Gynecologists advises against weight-loss medications during pregnancy. Women considering GLP-1 treatment should discuss the risks, benefits and timing with their healthcare professional, particularly if they plan to conceive.

What About Birth Control?

Tirzepatide, sold under the brand names Mounjaro and Zepbound, can affect oral contraceptive absorption. Its prescribing information recommends switching to a non-oral contraceptive method or adding a barrier method for four weeks after starting treatment and for four weeks after each dose increase.

Parkinson’s disease (PD) symptoms differ between women and men, a new study has found, with potential implications for treatment.

Presented at the 2026 International Congress of Parkinson’s Disease and Movement Disorders in Seoul, the study found that women experienced more severe motor complications and depression. Men, however, had greater cognitive impairment.

“Sex differences in movement disorders remain understudied and undervalued despite having an important impact on clinical outcomes in both real-life and clinical trial settings,” said Dr. Marina Picillo, assistant professor of neurology at AOU San Giovanni di Dio e Ruggi d’Aragona.

What Did The Study Find?

Researchers retrospectively analyzed 10 years of clinical data from more than 10,000 Parkinson’s patients examined at a movement disorders clinic in Germany.

The findings showed that women had a greater burden of motor complications and depression. Men were more likely to experience cognitive impairment, REM sleep behavior disorder (RBD) and loss of smell.

“By analyzing data for more than 10,000 PD patients, this study confirmed that depression is more common in women, while RBD, worse cognition, and poorer olfaction are more prevalent in men,” Picillo said. “With good representation of women (40%), it also confirmed a greater female burden of motor complications.”

How Could The Findings Help?

The findings highlight the need to account for sex differences in Parkinson’s disease management and clinical trial design, particularly given the historical underrepresentation of women in neurological research. However, the factors underlying these differences remain unclear.

Picillo stressed that considering sex differences when tailoring treatment and designing clinical trials could be an important first step toward precision medicine in Parkinson’s disease.

“This would be the very first, basic step for boosting precision medicine in PD,” she said.

What Is Parkinson’s Disease?

Parkinson’s disease is a progressive neurodegenerative disorder caused by the loss of dopamine-producing nerve cells in the brain.

Common symptoms include tremors, muscle stiffness, slowed movement and impaired balance. As the disease progresses, patients may have difficulty walking, speaking and performing everyday tasks.

The condition can also cause cognitive impairment, depression, anxiety, sleep disturbances, pain and swallowing difficulties, affecting patients’ independence and quality of life. Although it primarily affects older adults, younger people can also develop Parkinson’s disease.

Global Burden Of Parkinson’s Disease

Parkinson’s disease affected an estimated 11.9 million people worldwide in 2021. The number is projected to reach 25.2 million by 2050, a 112% increase.

Can Parkinson’s Disease Be Prevented?

There is currently no established way to prevent Parkinson’s disease. However, research suggests that certain lifestyle and environmental factors may influence disease risk.

• Physical activity: Regular exercise supports overall health, although its role in preventing Parkinson’s disease remains under investigation.
• Diet and nutrition: A balanced diet supports brain health, but no specific diet has been proven to prevent the disease.
• Environmental factors: Exposure to certain pesticides and other environmental pollutants has been associated with Parkinson’s disease risk. Reducing harmful exposures may help address potential risk factors.

A US lawsuit has accused feminine hygiene brand Carefree of exposing women to perfluorooctanoic acid (PFOA), a chemical linked to certain cancers. The complaint alleges that users developed health problems ranging from yeast infections to liver disease.

The lawsuit, filed in Los Angeles County Superior Court, claims the panty liners contained PFOA, a member of the per- and polyfluoroalkyl substances (PFAS) group, New York Post reported.

The women in the suit claim they suffered health problems, including breast, ovarian and kidney cancer; thyroid disease; chronic inflammation; infections; high cholesterol and immune disorders.

Others allegedly suffered reduced fertility or infertility, while the lawsuit claims the women now live in fear of developing cancer because of their alleged exposure.

“Each plaintiff suffered physical, mental, and emotional pain and suffering, anxiety over her diagnosis and treatment, and loss of enjoyment of life,” the papers state.

But can chemicals in panty liners pose a health risk? Scientific research has detected potentially harmful substances in menstrual products, raising questions about repeated exposure.

What Are PFOA And Forever Chemicals?

Also read: 43% Of Women With Autoimmune Diseases Say They Were Told It Was ‘All In Their Head’: Lancet

PFOA is a synthetic chemical belonging to the PFAS family, commonly known as forever chemicals because some can persist in the environment and human body for years.

Research has linked PFOA exposure to an increased risk of kidney and testicular cancers. Studies have also associated exposure with health concerns involving cholesterol, thyroid function and the immune system.

However, the risks depend on the chemical, the level and duration of exposure, and how it enters the body. The allegations against Carefree do not, by themselves, establish the extent of exposure from panty liners or the resulting health risks.

What Does Research Say About Chemicals In Panty Liners?

A February study published in Science of the Total Environment detected endocrine-disrupting chemicals (EDCs), including phthalates, bisphenols and parabens, in sanitary pads and panty liners.

Detection frequencies ranged from 75% to 100% in panty liners and 50% to 100% in sanitary pads. Phthalates were more prevalent in liners, while bisphenols were detected more frequently in pads.

The researchers estimated daily exposure doses of 2–20 nanograms per kilogram of body weight under normal skin-absorption assumptions, rising to 8–80 nanograms per kilogram under alternative exposure assumptions.

The findings highlight menstrual products as a potential source of chemical exposure, particularly when use is repeated over long periods and exposure occurs alongside other sources.

Some endocrine-disrupting chemicals have been investigated for their potential effects on hormonal and reproductive health. However, detecting these substances in menstrual products does not establish that using the products causes cancer.

More research is needed to determine how much of these substances is absorbed during normal use and whether the resulting exposure poses a measurable health risk.

Can Panty Liners Cause Irritation Or Infections?

Read More: More Women Buying Testosterone Without Prescription: Can It Help With Menopause?

Chemical exposure is not the only concern associated with panty liner use. Fragrances and other ingredients may trigger allergic reactions or contact dermatitis in people with sensitive skin.

Prolonged moisture and friction can also aggravate irritation around the vulva. Although liners do not necessarily cause bacterial or yeast infections, continuous use may cause discomfort in some people.

Persistent itching, unusual discharge or recurring irritation should be assessed by a healthcare professional.

How To Use Panty Liners More Safely

• Choose unscented liners: Fragrances may irritate sensitive skin.
• Change them regularly: Replace liners when damp or soiled to reduce prolonged moisture and friction.
• Avoid unnecessary use: Skip liners when you do not need them, particularly if they cause irritation.
• Check product information: Look for disclosures about materials and whether PFAS are intentionally added. Such claims do not guarantee the complete absence of these chemicals.
• Seek medical advice: Consult a healthcare professional if irritation or other symptoms persist.